LXRX - POTENTIAL BUY OPPORTUNITYLooking for a break (false break?) of crucial $1.70 support and in return expecting to see some opportunities arise for this cheap stock
LXRX trade ideas
LXRX potential to break out of wedgeMovements depend on corporate news but when good new is announced it has hge upside potential. Traders might play the technical break out too. However you may just have to sit on it for a while you never know when biotechs are going to pop but the wait is worth it when they do.
LXRX Testing 1-2 1-2I like this Chart
I like their numbers
I like my lines
LXRX is testing a new frontier... Stand by
LXRX LongTrying hard to breakout of the pullback channel. If it breaks out of the channel with volume in addition to a positive PR then the first target would be the gap fill of 4.16-4.25 and the next target would be 4.85. If it breaks down pull back support would be 2.96
$LXRX Fill The Gap And Go Or Will It Breakdown?LXRX is a penny stock that has performed well over the last few weeks but looking at the chart, shares are trading within the gap zone. Volume this week compared to previous weeks is lower. Is that a concern or just a slow week?
"Shares of LXRX stock have been on a tear for around a month. This was ever since terminating its partnership agreement with Sanofi. The termination gave Lexicon full control over its diabetes product Zynquista and in addition to that, Sanofi is going to pay the company as much as $260 million as a parting shot...The company will be conducting poster presentations of its XERMELO therapy this week at the North American Neuroendocrine Tumor Society Annual Multidisciplinary NET Medical Symposium." *
About LXRX
Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising drug targets. Lexicon then designs and develops drugs for these targets, which cover a broad spectrum of therapeutic areas. Following a restructuring in January 2014, Lexicon focused efforts on two drugs: sotagliflozin in diabetes, which is partnered with Sanofi, and Xermelo (telotristat etiprate) in carcinoid syndrome, which is partnered with Ipsen outside the U.S. Early-stage programs include SGLT1 inhibitor LX2761 and neuropathic pain drug LX9211.
*SOURCE: Are Penny Stocks Worth It? 3 Up Big In October
LXRX - Bullish But Risky Move. Pullback ComingLexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
SHORT INTEREST
7.74M 08/15/19
P/E Current
-1.51
P/E Ratio (with extraordinary items)
-2.05
Average Recommendation: OVERWEIGHT
Average Target Price: 8.00
